| Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck The new England Journal of Medicine, 2016 | 4714 | 2016 |
| Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced … SE Al-Batran, N Homann, C Pauligk, TO Goetze, J Meiler, S Kasper, ... The Lancet 393 (10184), 1948-1957, 2019 | 2052 | 2019 |
| Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by … RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... Oral oncology 81, 45-51, 2018 | 757 | 2018 |
| Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related … KJ Harrington, RL Ferris, G Blumenschein, AD Colevas, J Fayette, ... The Lancet Oncology 18 (8), 1104-1115, 2017 | 409 | 2017 |
| Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain F Heidel, FK Solem, F Breitenbuecher, DB Lipka, S Kasper, MH Thiede, ... Blood 107 (1), 293-300, 2006 | 324 | 2006 |
| Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind … D Soulières, S Faivre, R Mesía, É Remenár, SH Li, A Karpenko, ... The Lancet Oncology 18 (3), 323-335, 2017 | 210 | 2017 |
| Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. F Meric-Bernstam, SK Sandhu, O Hamid, A Spreafico, S Kasper, ... Journal of Clinical Oncology 37 (15_suppl), 2507-2507, 2019 | 145 | 2019 |
| A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML F Breitenbuecher, B Markova, S Kasper, B Carius, T Stauder, FD Böhmer, ... Blood, The Journal of the American Society of Hematology 113 (17), 4063-4073, 2009 | 139 | 2009 |
| The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer E Pastille, MH Wasmer, A Adamczyk, VP Vu, LF Mager, NNT Phuong, ... Mucosal immunology 12 (4), 990-1003, 2019 | 131 | 2019 |
| Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML) T Kindler, F Breitenbuecher, S Kasper, E Estey, F Giles, E Feldman, ... Blood 105 (1), 335-340, 2005 | 128 | 2005 |
| Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer E Pastille, K Bardini, D Fleissner, A Adamczyk, A Frede, M Wadwa, ... Cancer research 74 (16), 4258-4269, 2014 | 115 | 2014 |
| Stabilization of physical RAF/14-3-3 interaction by cotylenin A as treatment strategy for RAS mutant cancers M Molzan, S Kasper, L Röglin, M Skwarczynska, T Sassa, T Inoue, ... ACS chemical biology 8 (9), 1869-1875, 2013 | 107 | 2013 |
| Fatigue, barriers to physical activity and predictors for motivation to exercise in advanced Cancer patients J Frikkel, M Götte, M Beckmann, S Kasper, J Hense, M Teufel, M Schuler, ... BMC palliative care 19, 1-11, 2020 | 98 | 2020 |
| CheckMate 141: 1‐year update and subgroup analysis of nivolumab as first‐line therapy in patients with recurrent/metastatic head and neck cancer ML Gillison, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... The oncologist 23 (9), 1079-1082, 2018 | 97 | 2018 |
| Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies S Kasper, F Breitenbuecher, F Heidel, S Hoffarth, B Markova, M Schuler, ... Blood cancer journal 2 (3), e60-e60, 2012 | 97 | 2012 |
| Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study A Dasari, S Lonardi, R Garcia-Carbonero, E Elez, T Yoshino, A Sobrero, ... The Lancet 402 (10395), 41-53, 2023 | 88 | 2023 |
| Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a … R Haddad, F Concha‐Benavente, G Blumenschein Jr, J Fayette, J Guigay, ... Cancer 125 (18), 3208-3218, 2019 | 83 | 2019 |
| MET expression in advanced non–small-cell lung cancer: effect on clinical outcomes of chemotherapy, targeted therapy, and immunotherapy H Reis, M Metzenmacher, M Goetz, N Savvidou, K Darwiche, C Aigner, ... Clinical lung cancer 19 (4), e441-e463, 2018 | 72 | 2018 |
| High prevalence of concomitant oncogene mutations in prospectively identified patients with ROS1-positive metastatic lung cancer M Wiesweg, WEE Eberhardt, H Reis, S Ting, N Savvidou, C Skiba, ... Journal of Thoracic Oncology 12 (1), 54-64, 2017 | 69 | 2017 |
| Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN … RL Ferris, GR Blumenschein, J Fayette, J Guigay, AD Colevas, LF Licitra, ... Journal of Clinical Oncology 34 (15_suppl), 6009-6009, 2016 | 68 | 2016 |
Robert L. FerrisUniversity of Pittsburgh在 upmc.edu 的电子邮件经过验证
